Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mitoquinone - Antipodean Pharmaceuticals

Drug Profile

Mitoquinone - Antipodean Pharmaceuticals

Alternative Names: MitoQ; MitoQ10; Mitoubiquinone

Latest Information Update: 22 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antipodean Pharmaceuticals
  • Class Benzoquinones; Organophosphorus compounds
  • Mechanism of Action Antioxidants; Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatic fibrosis; Non-alcoholic fatty liver disease
  • Discontinued Alzheimer's disease; Cancer; Chemotherapy-induced damage; Diabetes mellitus; Friedreich's ataxia; Hypertension; Ischaemia; Parkinson's disease; Retinal disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 Sep 2015 No recent reports on development identified - Phase-II for Hepatic fibrosis (Prevention) in New Zealand (PO)
  • 22 Sep 2015 No recent reports on development identified - Phase-II for Non-alcoholic fatty liver disease in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top